secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001664710-23-000064
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics reports Q3 2023 net loss of $39.4M; advances KER-050, deprioritizes KER-047
--------------------------------------------------------------------------------

- Net loss of $39.4M in Q3 2023 vs $23.5M in Q3 2022, driven by increased R&D spending.
- R&D expenses rose to $34.1M from $21.0M; G&A rose to $9.1M from $6.9M.
- Cash and equivalents of $287.9M provide runway into Q4 2025.
- KER-047 program deprioritized; Phase 2 trial in MDS/myelofibrosis being terminated early.
- KER-065 Phase 1 trial in healthy adults expected to start in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/0001664710-23-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000064/kros-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001664710-23-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer